Search

Your search keyword '"Michelson, Eric"' showing total 273 results
Start Over Author "Michelson, Eric" Publication Type Academic Journals
273 results on '"Michelson, Eric"'

1. The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial: Results of the Continuous Electrocardiographic Assessment Substudy

Author

Scirica, Benjamin M., Cannon, Christopher P., Emanuelsson, Håkan, Michelson, Eric L., Harrington, Robert A., Husted, Steen, James, Stefan, Katus, Hugo, Pais, Prem, Raev, Dimitar, Spinar, Jindrich, Steg, Ph. Gabriel, Storey, Robert F., and Wallentin, Lars

Published
2011
Full Text
View/download PDF

11. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

Author

Ducharme, Anique, Swedberg, Karl, Pfeffer, Marc A., Cohen-Solal, Alain, Granger, Christopher B., Maggioni, Aldo P., Michelson, Eric L., McMurray, John J.V., Olsson, Lars, Rouleau, Jean L., Young, James B., Olofsson, Bertil, Puu, Margareta, and Yusuf, Salim

Subjects
Atrial fibrillation -- Prevention, Heart failure -- Complications and side effects, Heart failure -- Care and treatment, Mortality -- Evaluation, Cardiac patients -- Care and treatment, Angiotensin -- Receptors, Angiotensin -- Physiological aspects, Angiotensin -- Research, Health
Published
2006

12. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM)--added trial

Author

McMurray, John J.V., Young, James B., Dunlap, Mark E., Granger, Christopher B., Hainer, James, Michelson, Eric L., Earle, Steven, Olofsson, Bertil, Ostergren, Jan, Yusuf, Salim, Swedberg, Karl, and Pfeffer, Marc A.

Subjects
Angiotensin converting enzyme -- Research, Angiotensin converting enzyme -- Physiological aspects, Heart failure -- Research, Heart failure -- Care and treatment, Mortality -- Evaluation, Candesartan -- Research, Candesartan -- Physiological aspects, Health
Published
2006

13. Feasibility of treating prehypertension with an angiotensin-receptor blocker

Author

Julius, Stevo, Nesbitt, Shawna, Egan, Brent M., Weber, Michael A., Oparil, Suzanne, Schork, Anthony M., Michelson, Eric L., Kaciroti, Niko, Black, Henry R., Grimm, Richard H., and Messerli, Franz H.

Subjects
Hypertension -- Drug therapy, Candesartan -- Dosage and administration, Candesartan -- Research
Abstract

A test was conducted to investigate whether pharmacologic treatment of prehypertension prevents or postpones stage 1 hypertension. Treatment of prehypertension with candesartan appeared to be well tolerated and reduced the risk of incident hypertension indicating that pharmacological treatment of hypertension is feasible.

Published
2006

14. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial

Author

Granger, Bradi B., Swedberg, Karl, Ekman, Inger, Granger, Christopher B., Olofsson, Bertil, McMurray, John J.V., Yusuf, Salim, Michelson, Eric L., and Pfeffer, Marc A.

Subjects
Heart failure -- Risk factors, Heart failure -- Complications and side effects, Heart failure -- Care and treatment, Heart failure -- Analysis, Heart failure -- Patient outcomes
Published
2005

15. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure

Author

Demers, Catherine, McMurray, John J.V., Swedberg, Karl, Pfeffer, Marc A., Granger, Christopher B., Olofsson, Bertil, McKelvie, Robert S., Ostergren, Jan, Michelson, Eric L., Johansson, Peter A., Duolao Wang, and Yusuf, Salim

Subjects
Candesartan -- Dosage and administration, Candesartan -- Complications and side effects, Heart attack -- Drug therapy, Cardiac patients -- Medical examination
Abstract

A program is carried out with heart patients to study the effect of the angiotensin receptor blocker candesartan on myocardial infarction (MI) and other coronary disorders. Findings prove that the danger of the combined outcome of cardiovascular death or nonfatal MI markedly decreases with candesartan.

Published
2005

18. Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction

Author

Christian, Jennifer B., Finkle, John K., Ky, Bonnie, Douglas, Pamela S., Gutstein, David E., Hockings, Paul D., Lainee, Pierre, Lenihan, Daniel J., Mason, Jay W., Sager, Philip T., Todaro, Thomas G., Hicks, Karen A., Kane, Robert C., Ko, Hon-Sum, Lindenfeld, JoAnn, Michelson, Eric L., Milligan, James, Munley, Jiefen Y., Raichlen, Joel S., Shahlaee, Amir, Strnadova, Colette, Ye, Brenda, and Turner, Rick J.

Published
2012
Full Text
View/download PDF

21. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors

Author

Granger, Christopher B., Ertl, Georg, Kuch, Jerzy, Maggioni, Aldo P., McMurray, John, Rouleau, Jean-Lucien, Stevenson, Lynn Warner, Swedberg, Karl, Young, James, Yusuf, Salim, Califf, Robert M., Bart, Bradley A., Held, Peter, Michelson, Eric L., Sellers, Mary Ann, Ohlin, Gunilla, Sparapani, Rodney, and Pfeffer, Marc A.

Subjects
Angiotensin II receptor blockers -- Evaluation, Congestive heart failure -- Drug therapy, Health
Published
2000

22. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure – Assessment of Reduction in Mortality and morbidity (CHARM) programme

Author

Chang, Su Min, Granger, Christopher B., Johansson, Peter A., Kosolcharoen, Peter, McMurray, John J.V., Michelson, Eric L., Murray, David R., Olofsson, Bertil, Pfeffer, Marc A., Solomon, Scott D., Swedberg, Karl, Yusuf, Salim, and Dunlap, Mark E.

Published
2010
Full Text
View/download PDF

39. Thrombolytic therapy of acute myocardial infarction: keeping the unfulfilled promises

Author

Doorey, Andrew J., Michelson, Eric L., and Topol, Eric J.

Subjects
Thrombolytic drugs -- Health aspects, Heart attack -- Drug therapy
Abstract

Thrombolytic therapy may be used to prevent another heart attack in patients who have already suffered a severe heart attack. Thrombolytic therapy is treatment with different drugs to break up blood clots. A survey of the medical literature found that thrombolytic therapy can significantly decrease the number of complications and deaths among patients who have suffered a severe heart attack. Many patients who would benefit from this type of treatment do not receive it for a variety of reasons. Patients with high blood pressure or who have received cardiopulmonary resuscitation (CPR) often do not receive thrombolytic therapy, even though these conditions only slightly decrease their chance of benefiting from treatment. Elderly patients who have had a heart attack should not excluded from treatment on the basis on their age.

Published
1992

42. Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock.

Author

Samsky, Marc, Krucoff, Mitchell, Althouse, Andrew D., Abraham, William T., Adamson, Philip, Aguel, Fernando, Bilazarian, Seth, Dangas, George D., Gilchrist, Ian C, Henry, Timothy D., Hochman, Judith S., Kapur, Navin K., Laschinger, John, Masters, Roy G., Michelson, Eric, Morrow, David A., Morrow, Valarie, Ohman, E. Magnus, Pina, Ileana, and Proudfoot, Alastair G.

Published
2020
Full Text
View/download PDF

45. The Second Annual Think Tank on Prevention of Sudden Cardiac Death in the Young: Developing a rational, reliable, and sustainable national health care resource. A report from the Cardiac Safety Research Consortium.

Author

Aziz, Peter F., Berger, Stuart, Kowey, Peter, Krucoff, Mitchell, Lopez-Anderson, Martha, Michelson, Eric, Molossi, Silvana, Morrow, Valarie, Rodriguez, Ignacio, Saarel, Tess (Elizabeth), Strnadova, Colette, Vetter, Victoria, Wright, Theressa J., and Idriss, Salim F.

Abstract

Sudden cardiac death in the young (SCDY) spans gender, race, ethnicity, and socioeconomic class. The loss of any pediatric patient is a matter of national and international public health concern, and focused efforts should be aimed at preventing these burdensome tragedies. Prepared by members of the Cardiac Safety Research Consortium, this White Paper summarizes and reports the dialogue at the second Think Tank related to the issues and the proposed solutions for the development of a national resource for screening and prevention of SCDY. This Think Tank, sponsored by the Cardiac Safety Research Consortium and the United States Food and Drug Administration, convened on February 18, 2016, in Miami, FL, to identify and resolve the barriers that prevent early identification of patients at risk for SCDY. All potential stakeholders including national and international experts from industry, medicine, academics, engineering, and community advocacy leaders had an opportunity to share ideas and collaborate. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

46. Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial.

Author

Bui, An H., Cannon, Christopher P., Steg, Philippe Gabriel, Storey, Robert F., Husted, Steen, Guo, Jianping, Im, KyungAh, James, Stefan K., Michelson, Eric L., Himmelmann, Anders, Held, Claes, Varenhorst, Christoph, Wallentin, Lars, and Scirica, Benjamin M.

Subjects
PLATELET aggregation inhibitors, ADENOSINES, CARDIAC arrest, COMPARATIVE studies, CAUSES of death, ELECTROCARDIOGRAPHY, RESEARCH methodology, MEDICAL cooperation, PEPTIDE hormones, PEPTIDES, RESEARCH, RISK assessment, TICLOPIDINE, TIME, EVALUATION research, VENTRICULAR tachycardia, RANDOMIZED controlled trials, TREATMENT effectiveness, DISEASE incidence, ACUTE coronary syndrome, DISEASE complications, DIAGNOSIS, THERAPEUTICS
Abstract

Background: Nonsustained ventricular tachycardia (NSVT) is common after acute coronary syndrome (ACS) and a marker of increased risk of arrhythmogenic death. However, the prognostic significance of NSVT when evaluated with other contemporary risk markers and at later time points after ACS remains uncertain.Methods and Results: In the Platelet Inhibition and Patient Outcomes (PLATO) trial, continuous ECGs were performed during the first 7 days after ACS (n=2866) and repeated for another 7 days at day 30 (n=1991). Median follow-up was 1 year. There was a time-varying interaction between NSVT and cardiovascular death such that NSVT was significantly associated with increased risk within the first 30 days after randomization (22/999 [2.2%] versus 16/1825 [0.9%]; adjusted hazard ratio, 2.84; 95% confidence interval, 1.39-5.79; P=0.004) but not after 30 days (28/929 [3.0%] versus 42/1734 [2.4%]; P=0.71). Detection of NSVT during the convalescent phase (n=428/1991; 21.5%) was also associated with an increased risk of cardiovascular death, and was most marked within the first 2 months after detection (1.9% versus 0.3%; adjusted hazard ratio, 5.48; 95% confidence interval, 1.07-28.20; P=0.01), and then decreasing over time such that the relationship was no longer significant by ≈5 months after ACS.Conclusions: NSVT occurred frequently during the acute and convalescent phases of ACS. The risk of cardiovascular death associated with NSVT was the greatest during the first 30 days after presentation; however, patients with NSVT detected during the convalescent phase were also at a significantly increased risk of cardiovascular death that persisted for an additional several months after the index event.Clinical Trial Registration: http://www.clinicaltrials.gov. Unique identifier: NCT00391872. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results